KNSA vs. C

Last updated Apr 1, 2026

Compare and contrast key facts about Kiniksa Pharmaceuticals, Ltd. (KNSA) and Citigroup Inc. (C).

Performance

KNSA vs. C - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Kiniksa Pharmaceuticals, Ltd. (KNSA) and Citigroup Inc. (C). The values are adjusted to include any dividend payments, if applicable.

KNSA vs. C - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
KNSA Kiniksa Pharmaceuticals, Ltd.	16.73%	108.54%	12.77%	17.09%	27.27%	-33.39%	59.76%	-60.63%	44.27%
C Citigroup Inc.	-2.30%	70.38%	41.93%	18.98%	-22.09%	0.93%	-19.70%	57.82%	-23.89%

Fundamentals

EPS KNSA : $0.46 C : $7.64
PE Ratio KNSA : 104.54 C : 14.85
PEG Ratio KNSA : 1.01 C : 0.66
PS Ratio KNSA : 6.28 C : 1.44
Total Revenue (TTM) KNSA : $597.97M C : $147.32B
Gross Profit (TTM) KNSA : $315.52M C : $77.20B
EBITDA (TTM) KNSA : $45.10M C : $23.10B

Returns By Period

In the year-to-date period, KNSA achieves a 16.73% return, which is significantly higher than C's -2.30% return.

KNSA

• 1D: 5.36%
• 1M: 8.23%
• YTD: 16.73%
• 6M: 24.00%
• 1Y: 116.79%
• 3Y*: 64.79%
• 5Y*: 21.11%
• 10Y*: —

C

• 1D: 5.72%
• 1M: 2.92%
• YTD: -2.30%
• 6M: 12.99%
• 1Y: 63.91%
• 3Y*: 38.99%
• 5Y*: 13.06%
• 10Y*: 13.63%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

KNSA vs. C — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KNSA

KNSA Risk / Return Rank: 95
KNSA Sharpe Ratio Rank: 95
KNSA Sortino Ratio Rank: 94
KNSA Omega Ratio Rank: 93
KNSA Calmar Ratio Rank: 96
KNSA Martin Ratio Rank: 97

C

C Risk / Return Rank: 88
C Sharpe Ratio Rank: 90
C Sortino Ratio Rank: 85
C Omega Ratio Rank: 87
C Calmar Ratio Rank: 89
C Martin Ratio Rank: 91

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KNSA vs. C - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Kiniksa Pharmaceuticals, Ltd. (KNSA) and Citigroup Inc. (C). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	KNSA	C	Difference
Sharpe ratio Return per unit of total volatility	2.68	1.94	+0.74
Sortino ratio Return per unit of downside risk	3.46	2.36	+1.10
Omega ratio Gain probability vs. loss probability	1.44	1.35	+0.09
Calmar ratio Return relative to maximum drawdown	6.77	3.45	+3.33
Martin ratio Return relative to average drawdown	22.32	11.28	+11.04
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

KNSA vs. C - Sharpe Ratio Comparison

The current KNSA Sharpe Ratio is 2.68, which is higher than the C Sharpe Ratio of 1.94. The chart below compares the historical Sharpe Ratios of KNSA and C, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	KNSA	C	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.68	1.94	+0.74
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.40	0.45	-0.05
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.41	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.19	0.15	+0.05

Correlation

The correlation between KNSA and C is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

KNSA vs. C - Dividend Comparison

KNSA has not paid dividends to shareholders, while C's dividend yield for the trailing twelve months is around 2.08%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
KNSA Kiniksa Pharmaceuticals, Ltd.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
C Citigroup Inc.	2.08%	1.99%	3.10%	4.04%	4.51%	3.38%	3.31%	2.40%	2.96%	1.29%	0.71%	0.31%

Drawdowns

KNSA vs. C - Drawdown Comparison

The maximum KNSA drawdown since its inception was -83.06%, smaller than the maximum C drawdown of -98.00%. Use the drawdown chart below to compare losses from any high point for KNSA and C.

Drawdown Indicators

	KNSA	C	Difference
Max Drawdown Largest peak-to-trough decline	-83.06%	-98.00%	+14.94%
Max Drawdown (1Y) Largest decline over 1 year	-14.65%	-18.99%	+4.34%
Max Drawdown (5Y) Largest decline over 5 years	-60.19%	-47.80%	-12.39%
Max Drawdown (10Y) Largest decline over 10 years	—	-56.51%	—
Current Drawdown Current decline from peak	0.00%	-69.87%	+69.87%
Average Drawdown Average peak-to-trough decline	-41.00%	-43.42%	+2.42%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.86%	5.80%	-0.94%

Volatility

KNSA vs. C - Volatility Comparison

Kiniksa Pharmaceuticals, Ltd. (KNSA) and Citigroup Inc. (C) have volatilities of 10.16% and 9.95%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	KNSA	C	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.16%	9.95%	+0.21%
Volatility (6M) Calculated over the trailing 6-month period	24.78%	22.66%	+2.12%
Volatility (1Y) Calculated over the trailing 1-year period	43.96%	33.08%	+10.88%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	52.82%	28.91%	+23.91%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	63.61%	33.25%	+30.36%

Financials

KNSA vs. C - Profitability Comparison

The chart below illustrates the profitability comparison between Kiniksa Pharmaceuticals, Ltd. and Citigroup Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

KNSA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 97.26M and revenue of 180.86M. Therefore, the gross margin over that period was 53.8%.

C - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Citigroup Inc. reported a gross profit of 19.87B and revenue of 19.87B. Therefore, the gross margin over that period was 100.0%.

KNSA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 24.02M and revenue of 180.86M, resulting in an operating margin of 13.3%.

C - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Citigroup Inc. reported an operating income of 3.81B and revenue of 19.87B, resulting in an operating margin of 19.2%.

KNSA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 18.44M and revenue of 180.86M, resulting in a net margin of 10.2%.

C - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Citigroup Inc. reported a net income of 2.47B and revenue of 19.87B, resulting in a net margin of 12.4%.